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Abstract
Background: Patients undergoing liver transplantation with preexisting renal dysfunction are prone to further renal
impairment with the early postoperative use of Calcineurin-inhibitors. However, there is only little scientific
evidence for the safety and efficacy of de novo CNI free “bottom-up” regimens in patients with impaired renal
function undergoing liver transplantation. This is a single-center study pilot-study (PATRON07) investigating safety
and efficacy of CNI-free, “bottom-up” immunosuppressive (IS) strategy in patients undergoing liver transplantation
(LT) with renal impairment prior to LT.
Methods/Design: Patients older than 18 years with renal impairment at the time of liver transplantation eGFR
< 50 ml/min and/or serum creatinine levels > 1.5 mg/dL will be included. Patients in will receive a CNI-free
combination therapy (basiliximab, MMF, steroids and delayed Sirolimus). Primary endpoint is the incidence of
steroid resistant acute rejection within the first 30 days after LT. The study is designed as prospective two-step trial
requiring a maximum of 29 patients. In the first step, 9 patients will be included. If 8 or more patients show no
signs of biopsy proven steroid resistant rejection, additional 20 patients will be included. If in the second step a
total of 27 or more patients reach the primary endpoint the regimen is regarded to be safe and efficient.
Discussion: If a CNI-free-"bottom-up” IS strategy is safe and effective, this may be an innovative concept in contrast
to classic top-down strategies that could improve the patient short and long-time renal function as well as overall
complications and survival after LT. The results of PATRON07 may be the basis for a large multicenter RCT
investigating the new “bottom-up” immunosuppressive strategy in patients with poor renal function prior to LT.
http://www.clinicaltrials.gov-identifier: NCT00604357
Background
Medical Problem
Early renal dysfunction after liver transplantation (LT) is
reported with a frequency as high as 50% [1,2]. The
introduction of the MELD-based allocation system in
the Eurotransplant area in December 2006 led to an
increase of the proportion of liver transplant recipients
with renal dysfunction at the time of transplantation,
since creatinine became a key component for the alloca-
tion of liver allografts [3]. Major risk factors associated
with early posttransplant renal impairment are: preexist-
ing diabetes mellitus, time on the waiting list with end-
stage hepatic disease, application of blood products,
liver allograft dysfunction and toxicity of Calcineurin-
inhibitors (CNI) [4-11]. The risk of developing chronic
renal failure after LT is approximately 20% after 5 years,
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mortality risk[12] - and these are data from the pre-
MELD era. An additional problem in this specific
patient group (impaired renal function at the time of LT
and MELD-scores of 25 and/or higher), is a high risk
for developing infectious complications [13]. Studies
indicate that early infections are present in almost 85%
of all patients, and become the most common cause of
death early after transplantation. Notably, two-third of
infections in liver transplant patients occur within the
first 3 months after transplantation with a very high per-
centage (67%) of severe infections [14,15]. In general,
the inflammatory response associated with infection is
impaired by immunosuppressive drugs. This disturbed
regulation increases the susceptibility for a broad range
of normal and of opportunistic infections [13]. There-
fore, patients with high lab-MELD scores hypothetically
should require a rather low amount of immunosuppres-
sive (IS) drugs during the first days to weeks after trans-
plantation, while they are in a state of SIRS (systemic
inflammatory response syndrome)-like state [16,17].
Current treatment options
Most patients undergoing liver transplantation are trea-
ted with de-novo immunosuppressive protocol based on
a CNI (cyclosporine or tacrolimus) and one or two addi-
tional drugs like steroids, mycofenolate mofetil (MMF)
or induction therapy with anti-thymocyte globulin or
anti-CD25-monoclonal antibodies. Current paradigms
are based on a top-down strategy which is based on
initially high dose IS treatment with a reduction in case
of side-effects or complications. One of the major
adverse effects of CNI is nephrotoxicity, a deleterious
complication for long-term survival and quality of life
[13-15]. However, there are no IS approaches that con-
centrate on a complete avoidance or “bottom-up” strat-
egy, delaying the introduction of CNI or an mTOR-
inhibitor until the patient really does require additional
IS (acute rejection). To date there is only one prospec-
tively randomized trial that investigated the influence of
delayed, low-dose IS with Tacrolimus and MMF in
patients with normal renal function. In this trial patients
did profit from an early avoidance of Tacrolimus with
regards to renal function [18].
Aim of the pilot trial
The primary aim of this study concept is (I) to evaluate,
if a de novo CNI-free IS regimen in patients with preex-
isting renal impairment at the time-point of LT can be
applied safely with regards to steroid resistant acute
rejections within 30 days after LT. (II) The secondary
aim is to provide a therapeutic strategy that can improve
or at least preserve an impaired renal function. (III) In a
next consecutive sequential step we plan to perform a
prospectively randomized 3-armed pilot-study that com-
pares “bottom-up” CNI-free and CNI-containing IS regi-
mens after LT in patients with impaired renal function
and high-MELD-scores at the time-point of LT which
would mean a change in paradigm from “top-down” to
“bottom-up” IS strategies in at least a high risk popula-
tion undergoing LT.
Reducing the risk for severe perioperative renal dys-
function (requiring dialysis) can be beneficial for patients
with impaired renal function prior LT. It is likely that the
early avoidance and latter “bottom-up” introduction of
CNI and mTOR-inhibitors (everolimus or sirolimus) also
reduces the incidence of early infectious complications,
occurrence of hypertension, post-transplant diabetes
mellitus and maybe decreases the risk for post transplant
malignancies, the leading cause of death in patients
undergoing solid organ transplantation.
Methods and Design
General Considerations and Study Population
This is a single-center study concept consisting of a pro-
spective single-armed two-step pilot-trial (PATRON07)
investigating safety and feasibility of a CNI-free, “bot-
tom-up” IS strategy in patients undergoing LT with
renal impairment prior to LT. Patients will be followed-
up for one year after transplantation each. Since there is
no clinical evidence for this IS approach, we decided to
first perform an uncontrolled pilot-study investigating
the safety and feasibility of a completely CNI-free
approach
Objectives of the study concept
T h eo b j e c t i v eo fPATRON07 i st oe v a l u a t ead en o v o
CNI-free immunosuppressive regimen based on induc-
tion therapy with anti-CD25 monoclonal anti- body,
mycophenolate mofetil (MMF/MPA), and delayed
mTOR-inhibition. The primary endpoint is defined as
the incidence of steroid-resistant acute rejection within
the first 30 days after liver transplantation. It reflects the
early potential and feasibility of the proposed immuno-
suppressive regimen with regards to safety and efficacy.
In a liver transplant setting an acute rejection can be
controlled with steroid treatment and does not necessa-
rily mean an irreversible damage to the liver. Secondary
objectives include the incidence of acute rejection(s), the
number and the timing of acute rejections per patient
within the first year after transplantation. A critical sec-
ondary endpoint will be the development of renal func-
tion at 1 week, 1, 3, 6 and 12 months after liver
transplantation. This includes information on the num-
ber of patients requiring renal replacement therapy and
its duration. During follow-up of 1 year liver allograft
function, infectious complications, treatment failures
defined as introduction of CNIs as well as side-effects
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wound-healing, the incidence of hepatic artery thrombo-
sis and mortality will be explicitly documented and
investigated.
Trial Population
The collective we are aiming at are patients older than
18 years with a preexisting renal impairment at the time
of LT. Patients will be eligible if the eGFR < 50 ml/min
(Cockroft-Gault) and/or their serum creatinine levels
> 1.5 mg/dL.
Eligibility
Inclusion and exclusion criteria for PATRON07 are
shown in table 1. Patients will be screened consecutively
on the liver waiting list at Regensburg University and
asked for their willingness to participate in this trial.
Consent
Patients on the waiting list meeting the inclusion and
none of the exclusion criteria will be informed about
the possibility of participating in either PATRON07.
They will be fully informed about the trial, the proce-
dures, risks, potential benefits and treatment alternatives
as well as the study management, insurance and docu-
mentation of personal data with regard to meeting data
protection legislation.
Procedures of minimizing bias
PATRON07 is a non-controlled prospective trial at a
single high volume liver transplant -center, which will
reduce bias due to surgical learning effects.
Interventions
Pre- and Intraoperative Data
Baseline data will be documented including demo-
graphics, medical history, current medication, metabolic,
liver and renal function as well as history of renal
treatment. Intraoperative data (warm and cold ischemic
times, blood-loss, requirement for blood products, inci-
sion suture times) and donor data (age, sodium,
gamma-GT, body-mass index, infectious status) will be
also documented.
Treatment Regimen
Prior to reperfusion 500 mg Prednisolone will be admi-
nistered i.v. After the transplantation, a combination of
anti-CD25-mAB (basiliximab 20 mg on day 0 and day
4 after the procedure), and MMF 2g / d , 2 applications
per day i.v., later conversion to oral intake) will be
applied. On day 10 after LT Sirolimus will be intro-
duced with a loading dose of 5 mg/d. Thereafter a
dosage of 2 mg/d will be administered, aiming at
24 hours trough-levels for Sirolimus between 4 and
8 ng/mL. Steroids will be started on day 1 after trans-
plantation with 1 mg/kg BW and will be tapered every
2 days for 5 mg to a dosage of 20 mg and for 2.5 mg
every two days to 7.5 mg. Thereafter the dosage will be
reduced to 5 mg and 2.5 mg for 1 week each and elimi-
nated thereafter. Additionally, every patient with risk
constellation will receive cytomegalovirus (CMV) pro-
phylaxis and prophylaxis against Pneumocystis carinii
infection during the first 3 months after liver transplan-
tation (Figure 1).
Follow-Up
Every patient will be followed up for 1 year after trans-
plantation. The primary end-point will be at 30 days
after transplantation (Steroid resistant acute rejection).
During the first 30 days after transplantation there will
be 9 visits where laboratory values (liver, renal and
metabolic function, sirolimus trough levels), adverse
events and rejection episodes will be recorded. Addition-
ally there will be an ultrasound on day 1 after liver
transplantation and on day 10 prior to the initiation of
sirolimus to exclude hepatic artery thrombosis. Between
day 30 and 1 year after liver transplantation the patient
will be followed up to evaluate the long time outcome
Table 1 Key In- and Exclusion Criteria for PATRON07 and BUILT_01
Inclusion Criteria Exclusion Criteria
Patients undergoing primary liver transplantation. Patients with pre-transplant renal replacement therapy > 14 days.
Patients older than 18 years. Patients with platelets < 50.000/nl.
eGFR < 50 ml/min at the time point of transplantation Patients with triglycerides > 350 mg/dl and cholesterol > 300 mg/dl
refractory to optimal medical treatment prior to initiation of therapy with
mTOR inhibition.
Serum creatinine levels > 1.5 mg/dL at the time-point of transplantation Multiple organ graft recipients.
Patients with eGFR < 50 ml/min at the time point of transplantation or
Serum creatinine levels > 1.5 mg/dL at the time-point of transplantation
Patients with signs of a hepatic artery stenosis directly prior to initiation of
therapy with Sirolimus.
Patients with a psychological, familial, sociologic or geographic condition
potentially hampering compliance with the study protocol and follow-up
schedule.
Patients under guardianship (e.g. individuals who are not able to freely
give their informed consent).
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overview of planned examinations during follow-up.
Clinical Sites
The study will be carried out at Regensburg University
Medical Center.
Safety aspects
All information and observations collected during the
follow-up visits, as well as spontaneous reports from the
patient, relatives or any other medical staff will be docu-
mented. Is an event serious (SAE) or suspected and
unexpected (SUSAR) the particular authorities (BfArM
[Bundesbehörde für Arzneimittel] and the Regensburg
University Ethics Committee) will be informed. In case
the safety and/or efficacy of the proposed treatment
regimen will fail, the patient has to be switched to the
center specific treatment regimen that potentially pro-
vides highest security with regard to safety and efficacy.
Usually, this regimen will be based on a CNI. To evalu-
ate the safety and efficacy of the proposed immunosup-
pressive regimen, a data safety monitoring board will be
set up. After every third patient that finished the first 30
days period of the study, the monitoring board will
receive data on efficacy and safety obtained from the
patients. The board will consist of two physicians (one
nephrologist and one hepatologist), who are both not
involved in the study and independent from the conduct
of the trial.
Statistical Analysis and Number of patients needed
The trial is designed on the basis of a critical review of
the existing evident data on steroid- resistant acute
rejection in liver transplantation and the use of de novo
CNI-free immunosuppressive regimens. Steroid resistant
acute rejection is the interesting parameter for the
planned intervention since this is a threat for irreversible
a c u t er e j e c t i o na n do r g a nl oss. A prospective uncon-
trolled two-step design was chosen for several reasons:
t h e r ea r eh a r d l yd a t ao nad en o v oC N I - f r e ei m m u n o -
suppressive regimen. Therefore, we intended to design
an uncontrolled pilot-trial, which is feasible for a single
center, but is represented by a reasonable end-point.
The two-step design offers this possibility with the
i n c l u s i o no faf i r s tg r o u po f9p a t i e n t s ,ac o n s e c u t i v e
evaluation and decision if the trial has to be terminated
prematurely or if in the second step the hypothesis can
be further confirmed by including additional 20 patients
aiming at 29 patients in total [19]. This is a prospective,
open-label, two-stage study. The primary endpoint is the
Figure 1 IS treatment regimen for PATRON07. Basiliximab will be applied on day 0 and 4 after transplantation as 20 mg i.v. application, MMF
will be applied as 2 g/d bid, center-specific steroids will be applied and tapered by month 6 after LT, Sirolimus will no be started prior to day 10
after LT aiming at trough-levels of 4 to 10 ng/ml.
Table 2 Follow-up and planned interventions for PATRON 07
Day
0
Day
1
Day
2
Day
3
Day
4
Day 10 Day
14/15
Day
20/21
Day
25/26
Day
30
Month
3
Month 6 Month 12
Medical History
1 X
Transplant Data X
eGFR XXXXX X X X X X X X X
Laboratory
2 XXXXX X X X X X X X X
Ultrasound
3 XX X X X X
Rejection
4 XXXX X X X X X X X X
AE XXXXX X X X X X X X X
Sirolimus trough levels (4-10 ng/mL) XXX XX X X
1: focusing on liver disease, infectious history, concomitant renal disease
2: Na, K, creatinine, urea, GOT, GPT, AP, yGT, bilirubin, CHE, LDH, Quick, pTT, Hb, leucocytes, platelets, cholesterole and triglycerides (day 0 and 30)
3: Additional examinations in case of pathologic findings or indication.
4. laboratory signs of rejection (if suspected confirmed by biopsy)
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first 30 days after liver transplantation (LT). Based on
Cochrane database and Medline database data including
a total of 2.200 patients, the incidence of steroid resis-
tant rejection within the first year after transplantation
with the commonly used CNI-based and CNI-reduced
protocols is 12.5% of all patients undergoing LT. This
means that 87.5% of patients are without steroid resis-
tant rejection (i.e., the response proportion is 87.5%).
Based on this estimation a two-stage design [19] will be
applied to test the following statistical hypothesis: H0:
The true response probability p is less than the uninter-
esting level p0(p ≤ p0). Versus H1: The true response
probability p is at least the target level p1(p ≥ p1). In
this study, the uninteresting level will be defined as p0=
0.80, which means that 20% of our examined cohort
would experience a steroid resistant early acute rejection
within the first 30 days after LT. The target level will be
defined as p1= 0.95, which means that 5% of our collec-
tive would experience a steroid resistant early rejection
within the first 30 days. Under these assumptions,
9 patients will be enrolled in the first stage. After testing
the immunosuppressive regimen on 9 patients in the
first stage, the trial will be terminated if 7 or fewer
respond to the therapy. If the trial goes to the second
stage, an additional 20 patients will be enrolled. With a
total of 29 patients, the following decisions will be
made: If 26 or fewer responders are observed then H0
cannot be rejected. In this case, the immunosuppressive
therapy is not promising with a high probability and is
not worth to be tested in a greater trial for this indica-
tion. If 27 or more responders are observed, then H0
can be rejected. In this case, the immunosuppressive
regimen is considered promising. If the therapy is actu-
ally not promising, there is a 0.049 probability of con-
cluding that it is (the target significance level was set to
5%). If the therapy is actually promising, there is a 0.198
probability of concluding that it is not (the target for
this value was set to 20%). The confirmatory analysis
will be performed for the intent-to-treat population.
Figure 2 shows a statistical flowchart for the trial.
Trial organization, quality control and registration
The study was designed at Regensburg University Medi-
cal Center, Department of Surgery in cooperation with
the Regensburg University Medical Center, Center for
Clinical Studies. Quality assurance will be carried out in
cooperation with the Clinical Transplantation Study
Group of the Regensburg University Medical Center,
Department of Surgery. The studies will be monitored
by an independent monitor of the Clinical Transplanta-
tion Study Group. The studies will be performed in
accordance with the Declaration of Helsinki in its cur-
rent German version and the Good Clinical Practice/
International Committee of Harmonization-guidelines
(GCP/ICH). The study has been approved by the inde-
pendent Regensburg University Ethical Review Board on
November 16
th 2007. Final approval for the trial by the
BfArM has been obtained in November 2008 (EudraCT
number 2007-003561-40). The start of the study was
registered at the particular authority (Regierungsoberbe-
hörde der Oberpfalz in Regensburg) on January 15
th
2008. Additionally, it was registered under http://www.
clinicaltrials.gov on January 15
th 2008 (NCT00604357).
Financial support
PATRON07 is funded by an internal liver transplant
fund of the Department of Surgery at Regensburg Uni-
versity Medical Center.
Current status
PATRON07 started to actively recruit in December
2008 and currently has 9 patients included, which indi-
cates the first interim analysis. Data are currently
cleaned and evaluated.
Discussion
The PATRON07-study to establish CNI-free-"bottom-
up” strategies in LT recipients with renal impairment
prior to LT aims at minimizing IS in a “bottom-up”
approach in contrast to classical “top-down” strategies
aiming at improvement of renal impairment and infec-
tious complications in a specific group of highly ill liver
allograft recipients. PATRON07 is a prospective, non-
controlled, two-stage study. Its objective is to evaluate
the feasibility of a de novo CNI-free immunosuppressive
regimen based on induction therapy with anti-CD25
monoclonal anti- body, mycophenolate mofetil (MMF/
MPA), and mTOR-inhibition with sirolimus in patients
with impaired renal function at the time of liver trans-
plantation. The primary endpoint is defined as the inci-
dence of steroid-resistant acute rejection within the first
30 days after liver transplantation. It reflects the early
potential and feasibility of the proposed immunosup-
pressive regimen with regards to safety and efficacy. In a
liver transplant setting an acute rejection can be con-
trolled with steroid treatment and does not necessarily
mean an irreversible damage to the liver. Therefore,
classical endpoints in liver transplantation like renal out-
come measures or graft and patient survival will be of
interest once the completely new approach of bottom-
up immunosuppression has been established.
Former studies evaluated the effect of the reversibility
of CNI toxicity by introducing reduced or delayed CNI
based regimens or by switching patients to other sub-
stances like mTOR-inhibitors or MMF in a “top-down"-
fashion. Our intention with a de novo CNI free-"bot-
tom-up” IS strategies is to generally avoid CNI toxicity
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priori.
The study concept is designed as sequential concept per-
forming 2 separate independent clinical trials.
PATRON07 has to be performed as a first step since
t h e r ei sh a r d l yp u b l i s h e de v i d e n c ef o rC N I - f r e ed en o v o
approaches with mTOR-inhibitors in LT collectives. The
trial is designed as a prospective, uncontrolled, two-step
design according to Simon [19]. This is a major advantage
with regard to costs and feasibility of the trial. We intend
to prove the safety and efficacy of a therapy regimen that
has not been introduced in a prospective clinical setting in
liver transplantation. Therefore, we first need safe and
effective preliminary data from this pilot study to be able
to offer it to a broader collective of patients in a prospec-
tive randomized trial focusing on a different renal-specific
endpoint. With this design we found a suitable way to
address a specific scientific clinical problem in a prospec-
tive setting, which is feasible for one single center without
funding by a large pharmaceutical-company.
Conclusion
We conclude, that if CNI-free-"bottom-up” IS strategies
are safe and effective, this may be an innovative concept
that could improve the patient short and long-time out-
come with regards to renal function, infectious compli-
cations and avoidance of over-immunosuppression after
LT. The results of PATRON07 may be the basis for a
large multicenter RCT in patients with poor renal func-
tion at the time-point of LT.
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